NASDAQ: BFRI · Life Sciences · 3 alerts · CIK 1858685
Share price
$0.5700Close, Nov 16
Market cap
$10.2M
Shares outstanding
17.95MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Biofrontera Inc. filings on SEC EDGAR ↗
Biofrontera Inc. reported a net loss of $11.8 million for the nine months ended September 30, 2026, an improvement from the $16.2 million loss in the prior year period. Product revenues grew significantly to $31.2 million compared to $24.6 million in 2025, while the company's cash position decreased to $3.2 million as of the reporting date.
Biofrontera Inc. reported Q3 2026 net product revenue of $9.1 million, a 30% year-over-year increase driven by its photodynamic therapy products. The company achieved a significant regulatory milestone with the FDA approval of Ameluz for the treatment of superficial basal cell carcinoma. Net loss for the quarter narrowed slightly to $6.4 million compared to $6.6 million in the prior-year period.
Term
Q3 2026
“The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz® PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED® XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp.”
Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera